PARIS, April 18, 2017 /PRNewswire/ --
- See and quantify liver disease in a single exam
Chronic liver disease represents a major and rising public healthcare issue, affecting more than one billion people worldwide. It can be caused by a virus, such as hepatitis B or C, by excessive alcohol consumption or by dietary habits, resulting in conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
(Logo: Logo: http://photos.prnewswire.com/prnh/20160411/353647LOGO )
(Photo: Photo: http://mma.prnewswire.com/media/484464/Echosens_a.jpg )
These diseases generally remain symptomless and undetected until their very late stages but they progressively worsen over time and might ultimately lead to life-threatening complications, such as liver cirrhosis and liver cancer.
To further support clinicians in their fight against such diseases, Echosens and GE Healthcare have joined forces to offer a new integrated system, the LOGIQ™ S8 XDclear™ 2.0 ultrasound system[1], which will be presented at the International Liver Congress in Amsterdam. Combining best-in-class technologies in liver tissue quantification and in ultrasound imaging, this unique platform provides a wider range of solutions for the screening, diagnosis and monitoring of liver diseases.
Echosens has developed FibroScan®, the reference quantitative tool for the management of patients with chronic liver disease. FibroScan technology provides ultrafast and painless measurements of liver fibrosis, cirrhosis and steatosis, which are key parameters to assess liver condition. Recommended in the guidelines of prominent clinical organizations, including the World Health Organization (WHO), it has brought a non-invasive and cost-efficient alternative to painful liver biopsies, where a clinician inserted a needle into the liver to collect a tissue sample.
The LOGIQ™ S8 XDclear™ 2.0 is GE Healthcare's premium ultrasound system for a wide range of clinical uses. It offers a comprehensive Liver Package bringing leading-edge liver ultrasound imaging capabilities. Paired with FibroScan, it now gives clinicians a powerful and unique tool to see and quantify liver diseases in a single exam, supporting them with increased confidence and broader patient coverage.
Echosens and GE Healthcare are thrilled to partner to widen their panel of liver diagnostic solutions and contribute to improve outcomes in liver diseases.
- This system may not be available in all regions.
About Echosens:
Founded in 2001, Echosens is the world's leading provider of non-invasive diagnostic solutions dedicated to the assessment of chronic liver diseases. Its innovative products and services support clinicians in their management of patients with liver diseases, which affect more than one billion people worldwide. Echosens solutions are marketed in more than 80 countries, either directly or through a network of over 40 distributors. http://www.echosens.com
For any further information, please contact: Echosens Communication Dpt.
Share this article